Compare Amphastar Pharmaceuticals Inc (AMPH) vs Funko Inc (FNKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Funko Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Funko Inc trades at $6.23 (market cap $346.61M). The key difference: Amphastar Pharmaceuticals Inc is far larger — about 2.5× Funko Inc's market cap, and Funko Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | FNKO | |
|---|---|---|
Market Cap | $863.95M | $346.61M |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $6.35 |
52-Week Low | $16.87 | $2.65 |
Enterprise Value | $1.26B | $567.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Funko (FNKO) trades at $5.88, up 11.36% today, with strong technical momentum showing bullish signals across moving averages and oscillators. The company reported improved Q2 2026 results with net sales up 7% to $207.7 million and raised adjusted EBITDA guidance, though full-year 2025 showed a net loss of $67.36 million on $908.21 million revenue. Analyst sentiment is mixed with 42.9% buy ratings, while institutional ownership remains stable.
The outlook suggests potential recovery with recent earnings beats and strategic hires, but risks include persistent negative margins, high debt levels at 32.89% debt-to-asset ratio, and competitive pressures in the collectibles market. Valuation appears reasonable with P/S of 0.35 and EV/EBITDA of 6.41, offering upside if turnaround continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →
